medigraphic.com
Colegio de Medicina Interna de México.

2021, Number 4

<< Back Next >>

Med Int Mex 2021; 37 (4)

COVID-19: Cytokine storm or viral sepsis?

Sosa-Medellín MÁ, Ponce-Mendoza RA, Luviano-García JA, Almanza-Valdez HE, Maheda-García HJ, Santos-Macías JE, Tobías-Ortega JR, Cavazos-Obregón OH, Olvera-Carranza EE, Rodríguez-Segovia A, Vázquez-Ramírez R, Garcés-Estrada L, Pérez-Pérez LE

Language: Spanish
References: 21
Page: 580-585
PDF size: 260.34 Kb.


ABSTRACT

The infection by the new coronavirus that causes severe acute respiratory syndrome (SARS-CoV-2) made the World Health Organization (WHO) declare this infectious disease on January 30, 2020, as the sixth public health emergency at the international level. The clinical presentation of this disease can vary according to various factors of the infected patients, it can be divided into mild, moderate, severe and critical presentation. Sepsis is defined as an infection capable of generating a dysregulated response that causes organ failure. The SARS-CoV-2 infection generates an inflammatory syndrome similar to sepsis, therefore, we review the concept to answer if we are facing a septic process of viral origin.


REFERENCES

  1. Lai C, Shih T, Ko W, Tang H, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International J Antimicrob Agents 2020; 55: 105924. https://doi.org/10.1016/j.ijantimicag.2020.105924.

  2. RTVE Noticias. Coronavirus. El mapa mundial del coronavirus: más de 21,4 millones de casos y más de 766.000 muertos en todo el mundo. https://www.rtve.es/noticias/20200816/ mapa-mundial-del-coronavirus/1998143.shtml.

  3. Solano A, Solano A, Gamboa C. SARS-CoV-2: la nueva pandemia. Revista Médica Sinergia 2020; 5 (7).

  4. Shang, Y, Pan C, Yang X, Zhong M, et al. Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China. Ann Intensive Care 2020; 10: 73. https://doi.org/10.1186/ s13613-020-00689-1.

  5. Acter T, Uddin N, Das J, Akhter A, et al. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. Science of the Total Environment 2020; 730: 138996. https://doi.org/10.1016/j.scitotenv. 2020.138996.

  6. López-Pérez GT, Ramírez-Sandoval MLP, Torres-Altamirano MS. Fisiopatología del daño multiorgánico en la infección por SARS-CoV-2. Acta Pediatr Méx 2020; 41 (Supl 1): S27-S41.

  7. Amezcua L. Anotaciones breves sobre el síndrome de liberación de citocinas y el bloqueo terapéutico de la interleucina- 6 en SARS-CoV-2/COVID-19. Cardiovasc Metab Sci 2020; 31 (supl 3): s255-s258. https://dx.doi.org/10.35366/93956

  8. Song P, Li W, Xie J, Hou Y, et al. Cytokine storm induced by SARS-CoV-2. Clinica Chimica Acta 2020; 509: 280-287. https://doi.org/10.1016/j.cca.2020.06.017

  9. Rusell J, Rush B, Boyd J. Pathophysiology of septic shock. Crit Care Clin 2018; 34: 43-61. http://dx.doi.org/10.1016/j. ccc.2017.08.005.

  10. Avilés M, Figueira J, Agrifoglio A, Sánchez M. Bacteriemia, sepsis y shock séptico. Medicine 2018; 12 (52): 3066-75.

  11. Singer M, Deutschman C, Seymour C, Shankar-Hari M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315 (8): 801-10. doi. 10.1001/jama.2016.0287.

  12. Wilson J, Simpson L, Ferreira A, Rustagi A, et al. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight 2020; 5 (17): e140289. https:// doi.org/10.1172/jci.insight.140289.

  13. Colantuoni A, Martini R, Caprari P, Ballestri M, et al. COVID-19 sepsis and microcirculation dysfunction. Front Physiol 2020; 11: 747. doi. 10.3389/fphys.2020.00747.

  14. Rosario C, Zandman G, Meyron E, D’Cruz D, et al. The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Medicine 2013; 11: 185.

  15. Lachmann G, Knaak C, Vorderwülbecke G, La Rosée P, et al. Hyperferritinemia in critically ill patients. Critical Care Medicine 2020; 48 (4): 459-465. doi. 10.1097/ CCM.0000000000004131.

  16. Huang C, Wang Y, Li X, Ren L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506. https://doi.org/10.1016/ S0140-6736(20)30183-5.

  17. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infection 2020; 80: 607-613. https://doi.org/10.1016/j.jinf.2020.03.037.

  18. Li H, Liu L, Zhang D, Xu J, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 2020; 395: 1517-20. doi. 10.1016/S0140-6736(20)30920-X.

  19. Gu X, Zhou F, Wang Y, Fan G, et al. Respiratory viral sepsis: epidemiology, pathophysiology, diagnosis and treatment. Eur Respir Rev 2020; 26: 200038. https://doi. org/10.1183/16000617.0038-2020.

  20. Lin G, McGinley J, Drysdale S, Pollard A. Epidemiology and immune pathogenesis of viral sepsis. Front Immunol 2018; 9: 2147. doi. 10.3389/fimmu.2018.02147.

  21. Bonny V, Maillard A, Mousseaux C, Placais L, et al. COVID- 19: Pathogenesis of a multi-faceted disease. La Revue de médecine interne 2020; 41: 375-389. https://doi. org/10.1016/j.revmed.2020.05.003.




2020     |     www.medigraphic.com